Quantitative analysis of the impact of neovascular age-related macular degeneration (AMD) on the UK population has led a team of researchers to call for urgent, early access to the new class of drug therapies for the disease.
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.